A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease

Neurology

Volumn 47, Issue 3, 1996, Pages 705-711

  Thai, L J ^a   Carta, A ^b   Clarke, W R ^c   Ferris, S H ^d   Friedland, R P ^e   Petersen, R C ^f   Pettegrew, J W ^g   Pfeiffer, E ^h   Raskind, M A ⁱ   Sano, M ^j   Tuszynski, M H ^k   Woolson, R F ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sigma Tau SpA   (Italy)

^c UNIVERSITY OF IOWA   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j Columbia University ^*  (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVACECARNINE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

EID: 9544240348     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.3.705     Document Type: Article

References (51)

1. Katzman R. The prevalence of malignancy of Alzheimer's disease. Arch Neurol 1976;33:217-218.
2. Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990;68:267-289.
3. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30:572-580.
4. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990;27:457-464.
5. Burlina AP, Sershen H, Debler EA, Lajtha A. Uptake of acetyl-L-carnitine in the brain. Neurochem Res 1989;14:489-493.
6. Lehninger AL. Principles of biochemistry. New York: Worth Publishers, 1982.
7. Fände SV, Noel H, Murthy MSR. Characteristics of, function of, and deficiency of carnitine acylcarnitine translocase. In: Borum PR, ed. Clinical aspects of human carnitine deficiency. New York: Pergamon Press, 1986:165-180.
8. Carta A, Calvani M, Bravi D, Bhuachalla SN. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere. Ann NY Acad Sei 1993; 695:324-326.
9. Janiri L, Falcone M, Persico A, Tempesta E. Activity of L-carnitine and L-acetylcarnitine on cholinoceptive neocortical neurons of the rat in vivo. J Neurotrans 1991;86:135-146.
10. White HL, Scales PW. Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem Res 1990;15:597-601.
11. Aureli T, Miccheli A, Ricciolini R, et al. Aging brain: effect of acetylcarnitine treatment on rat brain energy and phospholipid metabolism: a study by 31P/1H/NMR spectroscopy. Brain Res 1990;526:108-112.
12. Villa RF, Gorini A. Action of acetyl-L-carnitine on different cerebral mitochondrial populations from hippocampus and striatum during aging. Neurochem Res 1991;16:1125-1132.
13. Petruzzella V, Baggetto LG, Penin F, et al. In vivo effect of acetyl-L-carnitine on succinate oxidation adenine nucleotides pool and lipid composition of synaptic and non-synaptic mitochondria from cerebral hemispheres of senescent rat. Arch Gerontol Geriatr 1992;14:131-144.
14. Fariello RG, Ferraro TN, Golden GT, DeMattei M. Systemic acetyl-L-carnitine elevates nigral levels of glutathione and GABA. Life Sei 1988;43:289-292.
15. Markowska AL, Ingram DK, Barnes ÇA, et al. Acetyl-L-carnitine 1: Effects on mortality, pathology and sensory motor performance in aging rats. Neurobiol Aging 1990;ll:491-497.
16. Tangliatela G, Navarra D, Cruciani R, Ramacci MT, Alema GS, Anagelucci L. ALCAR treatment increases nerve growth factor levels in the CNS of aged rats. Exp Gerontol 1994;29: 55-66.
17. Piovesan P, Pacifici L, Taglialatela G, Ramacci MT, Angelucci L. ALCAR treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following fimbria fornix transection. Brain Res 1994;633:77-82.
18. Girardi O, Caprioli A, Milano S, Guiliani A, Ramacci MT, Angelucci L. Active avoidance learning in old rats chronically treated with ALCAR. Physiol Behav 1992;52:185-187.
19. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, De Long MR. Alzheimer's disease and single dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
20. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1483.
21. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991; 41:1726-1732. .
22. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992;49:1137-1141.
23. Rai G, Wright G, Scott L, et al. Double-blind, placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 1990;ll:638-647.
24. Livingston GA, Sax KB, McClenahan Z, et al. Acetyl-L-carnitinc in dementia. Int J Geriatr Psychiatry 1991;6:853-860.
25. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995;16: 1-4.
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed rev. Washington, DC: American Psychiatric Association, 1987.
28. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. J Psychiatr Res 1975;12:189-198.
29. Rosen WG, Terry RD, Fuld PAA, Katzman R, Peck A. Pathological verification of ischémie score in differentiation of dementia. Ann Neurol 1980;7:486-488.
30. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
31. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for staging of dementia. Br J Psychiatry 1982;140:566-572.
32. Lawton MP, Brody EM. Assessment of older people: selfmaintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
33. Clinical global impressions. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Rev ed. Rockville, MD: Department of Health, Education and Welfare, 1976;218-222 (DHEW publication no (ADM) 76-338.)
34. Freiss JL. Analysis of data from multiclinic trials. Control Clin Trials 1986;7:267-275.
35. Landis JR, Heyman ER. Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Statis Rev 1978;46:237-254.
36. Freels S, Cohen D, Eisdorfer G, et al. Functional status and clinical findings in patients with Alzheimer's disease. J Gerontol 1992;47:M177-M182.
37. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988;24:458-462.
38. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992;31:242-249.
39. Morris JC, Edland S, Clark C, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993;43:2457-2465.
40. Stern RG, Mohs RC, Davidson M, et al. Searcey T, Bierer L, Davis KL. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:3.
41. Katzman R, Brown T, Thal LJ, et al. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease. Ann Neurol 1988;24:384-389.
42. Ortof E, Crystal HA. Rate of progression of Alzheimer's disease. J Am Geriatr Soc 1989;37:511-514.
43. Burns A, Jacoby R, Levy R. Progression of cognitive impairment of Alzheimer's disease. J Am Geriatr Soc 1991;39:39-45.
44. Col NF, Luckmann RS, Bigelow C, Fox P, Robertson A. Age as a predictor of functional decline in Alzheimer's disease [abstract]. J Am Geriatr Soc 1993;41(suppl A):47.
45. Seltzer B, Sherwin I. A comparison of clinical features in early- and late-onset primary degenerative dementia. Arch Neurol 1983;40:143-146.
46. Bondareff W, Mountjoy CQ, Roth M, Rossor MN, Iversen LL, Reynolds GP. Age and histopathologic heterogeneity in Alzheimer's disease: evidence of subtypes. Arch Gen Psychiatry 1987;44:412-417.
47. Schellenberg GD, Bird T, Wijsman EM, et al. Genetic linkage for a familial Alzheimer's disease locus on chromosome 14. Science 1992;258:668-671.
48. St. George-Hyslop P, Haines J, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet 1992;2:330-334.
49. Corder EH, Saunders AM, Strittmatter WJ, et al. Gène dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 1993;261:921-923.
50. Small GW, Kühl DE, Reige WH, et al. Cerebral glucose metabolic patterns in Alzheimer's disease: effect of gender and age at dementia onset. Arch Gen Psychiatry 1989;46:527-532.
51. Scheltens PH, Barkhof F, Valk J, et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease: evidence for heterogeneity. Brain 1992;115: 735-748.